|
Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab. |
|
|
Consulting or Advisory Role - Janssen Oncology; Pfizer |
Speakers' Bureau - Ipsen; Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Dompè; EMD SERONO; Ignyta; Incyte; Novartis; Octimet; Pfizer; Pharm Research associated; Pierre Fabre; Roche; Teofarma |
Speakers' Bureau - Bristol-Myers Squibb; Menarini; MSD; Novartis; Pfizer; Roche |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SERVIER (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Menarini; Merck; Novartis; Pfizer |
|
|
No Relationships to Disclose |